Alkermes plc - Ordinary Shares (ALKS): Price and Financial Metrics

Alkermes plc - Ordinary Shares (ALKS): $30.29

-0.10 (-0.33%)

POWR Rating

Component Grades













Add ALKS to Watchlist
Sign Up

Industry: Biotech



in industry


  • Growth is the dimension where ALKS ranks best; there it ranks ahead of 99.76% of US stocks.
  • The strongest trend for ALKS is in Quality, which has been heading down over the past 179 days.
  • ALKS ranks lowest in Momentum; there it ranks in the 12th percentile.

ALKS Stock Summary

  • ALKS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 138.33 -- higher than 82.94% of US-listed equities with positive expected earnings growth.
  • Alkermes plc's stock had its IPO on July 16, 1991, making it an older stock than 83.46% of US equities in our set.
  • Price to trailing twelve month operating cash flow for ALKS is currently 44.57, higher than 88.09% of US stocks with positive operating cash flow.
  • Stocks that are quantitatively similar to ALKS, based on their financial statements, market capitalization, and price volatility, are THRM, MRIN, CLXT, ACLS, and SMSI.
  • ALKS's SEC filings can be seen here. And to visit Alkermes plc's official web site, go to

ALKS Valuation Summary

  • In comparison to the median Healthcare stock, ALKS's EV/EBIT ratio is 519.45% lower, now standing at -122.9.
  • Over the past 243 months, ALKS's EV/EBIT ratio has gone down 53.7.
  • ALKS's price/sales ratio has moved down 32.4 over the prior 243 months.

Below are key valuation metrics over time for ALKS.

Stock Date P/S P/B P/E EV/EBIT
ALKS 2021-08-31 4.6 4.6 -80.3 -122.9
ALKS 2021-08-30 4.6 4.6 -80.7 -123.4
ALKS 2021-08-27 4.6 4.6 -79.9 -122.3
ALKS 2021-08-26 4.5 4.5 -78.4 -120.1
ALKS 2021-08-25 4.5 4.5 -78.7 -120.6
ALKS 2021-08-24 4.5 4.5 -78.0 -119.5

ALKS Growth Metrics

    Its 3 year revenue growth rate is now at 75.07%.
  • The 4 year price growth rate now stands at -65.14%.
  • The 5 year cash and equivalents growth rate now stands at -11.96%.
ALKS's revenue has moved up $549,856,000 over the prior 70 months.

The table below shows ALKS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1,173.751 101.715 -48.169
2021-09-30 1,129.283 138.037 -91.684
2021-06-30 1,100.154 115.463 -62.83
2021-03-31 1,043.966 77.968 -94.625
2020-12-31 1,038.756 82.842 -110.861
2020-09-30 1,171.491 57.569 -73.573

ALKS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALKS has a Quality Grade of B, ranking ahead of 88.71% of graded US stocks.
  • ALKS's asset turnover comes in at 0.582 -- ranking 63rd of 680 Pharmaceutical Products stocks.
  • OTLK, AVEO, and LXRX are the stocks whose asset turnover ratios are most correlated with ALKS.

The table below shows ALKS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.582 0.835 -0.047
2021-06-30 0.576 0.836 -0.029
2021-03-31 0.556 0.835 -0.050
2020-12-31 0.557 0.828 -0.061
2020-09-30 0.641 0.845 -0.034
2020-06-30 0.646 0.844 -0.076

ALKS Price Target

For more insight on analysts targets of ALKS, see our ALKS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.50 Average Broker Recommendation 1.88 (Hold)

ALKS Stock Price Chart Interactive Chart >

Price chart for ALKS

ALKS Price/Volume Stats

Current price $30.29 52-week high $33.00
Prev. close $30.39 52-week low $21.24
Day low $29.91 Volume 1,104,400
Day high $30.57 Avg. volume 1,469,318
50-day MA $28.65 Dividend yield N/A
200-day MA $26.86 Market Cap 4.95B

Alkermes plc - Ordinary Shares (ALKS) Company Bio

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 and is based in Dublin, Ireland.

ALKS Latest News Stream

Event/Time News Detail
Loading, please wait...

ALKS Latest Social Stream

Loading social stream, please wait...

View Full ALKS Social Stream

Latest ALKS News From Around the Web

Below are the latest news stories about Alkermes plc that investors may wish to consider to help them evaluate ALKS as an investment opportunity.

For Individuals With Bipolar 1 Disorder Finding the Right Treatment Can Be a Long and Difficult Process

Our recent survey conducted with Harris Poll and Depression and Bipolar Support Alliance found that many individuals with Bipolar 1 disorder felt that finding the right treatment can be a long and ...

Yahoo | February 23, 2022

Black History Month and Mental Health

#BlackHistoryMonth represents an opportunity to highlight the disparities within the Black community when it comes to mental health. According to a 2018 survey, 50% of Black adults with serious men...

Yahoo | February 21, 2022

Alkermes (ALKS) Gets a Buy Rating from Mizuho Securities

In a report released today, Vamil Divan from Mizuho Securities reiterated a Buy rating on Alkermes (ALKS – Research Report), with a price target of $35.00. The company's shares closed last Wednesday at $26.79. According to, Divan is a 1-star analyst with an average return of -2.1% and a 48.1% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, ACADIA Pharmaceuticals, and Xeris Pharmaceuticals. Currently, the analyst consensus on Alkermes is a Moderate Buy with an average price target of $29.33, which is a 23.5% upside from current levels.

Catie Powers on TipRanks | February 17, 2022

Alkermes Reports Stellar Quarterly Beat; Shares Surge 15%

Alkermes (NASDAQ: ALKS) shares jumped almost 15% on February 16, after the company delivered impressive fourth-quarter results topping both earnings and revenue estimates. Furthermore, the company provided strong FY2022 guidance and provided bullish long-term profitability targets. Alkermes is a global biopharmaceutical company that develops innovative medicines in the fields of neuroscience and oncology. Q4 Beat Markedly, adjusted earnings of $0.23 per share more than doubled year-over-year and significantly beat analysts’ expectations of $0.11 per share. The company reported earnings of $0.10 per share for the prior-year period. Further, revenues jumped 15.9% year-over-year to $324.5 million and exceeded consensus estimates of $308.88 million.

Devina Lohia on TipRanks | February 17, 2022

Alkermes'' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer

Alkermes plc (NASDAQ: ALKS ) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) variant immunotherapy for advanced renal cell carcinoma (RCC). The data were presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium. The presentation includes updated efficacy and safety data from the monotherapy arm of ARTISTRY-1, in which … Full story available on

Benzinga | February 17, 2022

Read More 'ALKS' Stories Here

ALKS Price Returns

1-mo 1.47%
3-mo 7.95%
6-mo 30.22%
1-year 23.53%
3-year 32.56%
5-year -47.75%
YTD 30.22%
2021 16.59%
2020 -2.21%
2019 -30.87%
2018 -46.08%
2017 -1.53%

Continue Researching ALKS

Want to see what other sources are saying about Alkermes plc's financials and stock price? Try the links below:

Alkermes plc (ALKS) Stock Price | Nasdaq
Alkermes plc (ALKS) Stock Quote, History and News - Yahoo Finance
Alkermes plc (ALKS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6124 seconds.